Milad Shafizadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Milad Shafizadeh has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Amin Habibi
Department of neurosurgery, Shariati hospital, Tehran University of medical sciences, Tehran, Iran
5 shared publications - Bardia Hajikarimloo
Department of Neurological Surgery, University of Virginia, Charlottesville, USA
4 shared publications - Amirhossein Kamroo
Department of neurosurgery, Shariati hospital, Tehran University of medical sciences, Tehran, Iran
3 shared publications - Ibrahim Mohammadzadeh
Skull Base Research Center, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications - Mohsen Rostami
Department of Neurosurgery, Brain and Spine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
3 shared publications - Sadegh Bagherzadeh
Department of neurosurgery, Shariati hospital, Tehran University of medical sciences, Tehran, Iran
3 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 24 (1)
Medical research barriers, facilitators, and motives in a developing country: a mixed-methods single-centre study
- 22 July 2026
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 24 (1)
Open AccessMedical research barriers, facilitators, and motives in a developing country: a mixed-methods single-centre study
- Open Access
- 7 July 2026
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 168 (1)
Hypofractionated stereotactic radiotherapy/radiosurgery versus single-session stereotactic radiosurgery for patients with hemangioma of cavernous sinus: a systematic review, single-arm meta-analysis, and an indirect comparison
Background Cavernous sinus hemangiomas (CSHs) are rare, benign vascular tumors with high morbidity due to their critical location and vascularity. While microsurgical resection was the historical standard, its risks of intraoperative bleeding and cranial nerve deficits have led to the adoption of stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (HSRT). This systematic review and meta-analysis evaluate outcomes of these modalities, focusing on tumor control, symptom relief, and safety. Methods Following PRISMA guidelines, a systematic search of PubMed, Embase, Web of Science, and Scopus (up to March 2024) identified studies reporting outcomes of SRS or HSRT in CSHs. Eligible studies were assessed for quality using the Joanna Briggs Institute checklist. All statistical analysis was performed using STATA v.17. Results Twenty studies with 682 patients were included. Tumor volume reduction was substantial, with a pooled estimate of 71% (95% CI: 57–84%) and a standardized mean difference of -2.07 (95% CI: -2.47 to -1.67). Symptom recovery rates were highest with HSRT (64%, 95% CI: 9–119%) compared to SRS (44%, 95% CI: 21–67%). Adverse radiation effects were minimal, with an overall rate of 5% (95% CI: 2–7%). Cranial nerve improvement was observed but varied by nerve and treatment type. Conclusion SRS and HSRT are effective and safe for CSHs, with HSRT showing particular benefits for larger tumors due to fractionation. Future studies should optimize protocols and refine patient selection to maximize therapeutic outcomes. Radiation-based therapies now represent a cornerstone in CSH management.
- 7 July 2026
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 168 (1)
Open AccessHypofractionated stereotactic radiotherapy/radiosurgery versus single-session stereotactic radiosurgery for patients with hemangioma of cavernous sinus: a systematic review, single-arm meta-analysis, and an indirect comparison
Background Cavernous sinus hemangiomas (CSHs) are rare, benign vascular tumors with high morbidity due to their critical location and vascularity. While microsurgical resection was the historical standard, its risks of intraoperative bleeding and cranial nerve deficits have led to the adoption of stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (HSRT). This systematic review and meta-analysis evaluate outcomes of these modalities, focusing on tumor control, symptom relief, and safety. Methods Following PRISMA guidelines, a systematic search of PubMed, Embase, Web of Science, and Scopus (up to March 2024) identified studies reporting outcomes of SRS or HSRT in CSHs. Eligible studies were assessed for quality using the Joanna Briggs Institute checklist. All statistical analysis was performed using STATA v.17. Results Twenty studies with 682 patients were included. Tumor volume reduction was substantial, with a pooled estimate of 71% (95% CI: 57–84%) and a standardized mean difference of -2.07 (95% CI: -2.47 to -1.67). Symptom recovery rates were highest with HSRT (64%, 95% CI: 9–119%) compared to SRS (44%, 95% CI: 21–67%). Adverse radiation effects were minimal, with an overall rate of 5% (95% CI: 2–7%). Cranial nerve improvement was observed but varied by nerve and treatment type. Conclusion SRS and HSRT are effective and safe for CSHs, with HSRT showing particular benefits for larger tumors due to fractionation. Future studies should optimize protocols and refine patient selection to maximize therapeutic outcomes. Radiation-based therapies now represent a cornerstone in CSH management.
- Open Access
- 6 March 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 132
Bilateral subdural hematomas in spontaneous intracranial hypotension: A systematic review with case illustration
Background: Spontaneous intracranial hypotension (SIH) is a well-recognized but often underdiagnosed cause of secondary subdural hematoma (SDH), particularly in younger patients who frequently present with bilateral collections. The role of lumbar puncture (LP) remains controversial in this setting, as additional cerebrospinal fluid removal may destabilize intracranial pressure and precipitate or worsen SDH. Methods: We performed a systematic review of SIH cases associated with bilateral SDH. When possible, we reconstructed a patient-level dataset to analyze clinical presentation, LP context, management strategies, and outcomes. We also describe a middle-aged man with orthostatic headache and fever who presented with thin, chronic-appearing bilateral SDH in the setting of SIH. Following a diagnostic LP performed to exclude meningitis, he developed a rapidly progressive, extensive bilateral mixed-density SDH requiring urgent burr-hole evacuation. Results: Fifty-nine studies were included, totaling 485 patients with SIH, of whom 182 had bilateral SDH. From these, we assembled a patient-level cohort of 59 individuals with SIH-associated SDH. The mean age was 47 years, and 81.4% were male. Orthostatic headache was present in 76.3%, whereas coma or stupor occurred in 25.4%. In this cohort, 62.7% had no LP, 30.5% underwent LP only after SDH diagnosis, and 6.8% had clearly post-LP SDH. Management included SDH surgery in 67.8%, epidural blood patch in 67.8%, and open leak repair in 11.9%. The overall SDH recurrence rate was 27.1%, with the highest recurrence (55.6%) in patients who underwent LP after SDH recognition. No deaths were reported. Conclusion: Bilateral SDH in the context of SIH mainly affects younger patients and requires a combined strategy of SDH evacuation (when indicated) and leak-directed therapy. Although true post-LP bilateral SDH appears uncommon, LP may reveal or amplify an already unstable low-pressure state. Given the low certainty and incomplete temporal data in many reports, our findings support cautious consideration and avoidance of routine LP solely to document opening pressure in suspected SIH.
- 6 March 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 132
Open AccessBilateral subdural hematomas in spontaneous intracranial hypotension: A systematic review with case illustration
Background: Spontaneous intracranial hypotension (SIH) is a well-recognized but often underdiagnosed cause of secondary subdural hematoma (SDH), particularly in younger patients who frequently present with bilateral collections. The role of lumbar puncture (LP) remains controversial in this setting, as additional cerebrospinal fluid removal may destabilize intracranial pressure and precipitate or worsen SDH. Methods: We performed a systematic review of SIH cases associated with bilateral SDH. When possible, we reconstructed a patient-level dataset to analyze clinical presentation, LP context, management strategies, and outcomes. We also describe a middle-aged man with orthostatic headache and fever who presented with thin, chronic-appearing bilateral SDH in the setting of SIH. Following a diagnostic LP performed to exclude meningitis, he developed a rapidly progressive, extensive bilateral mixed-density SDH requiring urgent burr-hole evacuation. Results: Fifty-nine studies were included, totaling 485 patients with SIH, of whom 182 had bilateral SDH. From these, we assembled a patient-level cohort of 59 individuals with SIH-associated SDH. The mean age was 47 years, and 81.4% were male. Orthostatic headache was present in 76.3%, whereas coma or stupor occurred in 25.4%. In this cohort, 62.7% had no LP, 30.5% underwent LP only after SDH diagnosis, and 6.8% had clearly post-LP SDH. Management included SDH surgery in 67.8%, epidural blood patch in 67.8%, and open leak repair in 11.9%. The overall SDH recurrence rate was 27.1%, with the highest recurrence (55.6%) in patients who underwent LP after SDH recognition. No deaths were reported. Conclusion: Bilateral SDH in the context of SIH mainly affects younger patients and requires a combined strategy of SDH evacuation (when indicated) and leak-directed therapy. Although true post-LP bilateral SDH appears uncommon, LP may reveal or amplify an already unstable low-pressure state. Given the low certainty and incomplete temporal data in many reports, our findings support cautious consideration and avoidance of routine LP solely to document opening pressure in suspected SIH.
- Open Access
- 23 February 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
The clinical benefit of adding anlotinib to chemoradiothearpy in high-grade gliomas: a systematic review, meta-analysis, and specific analysis on glioblastoma
Anlotinib, a novel multi-target tyrosine kinase inhibitor, has shown promise in improving survival and managing associated complications. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Anlotinib in patients with high-grade glioma, specifically glioblastoma (GBM). This study was conducted according to the PRISMA guidelines. A systematic search was conducted on PubMed, Embase, Web of Science, and Scopus up to 9 December 2024. The included studies were appraised and assessed for quality and potential bias and further statistical analyses were performed using STATA v.17. A total of 17 studies with 473 patients were recruited, which included 204 patients with GBM. The pooled analysis resulted in a 6-month OS of 67% (95% CI: 42–92%) and a 1-year OS equal to 50% (95% CI: 36–64%) from the Anlotinib treatment. Progression-free survival at 6 months was 61% (95% CI: 46–75%), and at 1 year was 27% (95% CI: 13–41%), also showing similar promising outcomes. The overall response rate (ORR) and disease control rate (DCR) were reported at 55% (95% CI: 44–67%) and 90% (95% CI: 87–94%), respectively. The sub-group analysis revealed that adding anlotinb to temozolomide (TMZ) and radiotherapy had superior outcomes regarding OS, PFS, and DCR. Moreover, the highest ORR and complete response rate were achieved by Anlotinib plus stereotactic radiosurgery. Anlotinib demonstrates considerable efficacy in extending survival and achieving disease control in high-grade glioma patients when added to radiotherapy and TMZ. These findings can support its inclusion in therapeutic regimens, warranting further investigation in large-scale randomized controlled trials.
- 23 February 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
Open AccessThe clinical benefit of adding anlotinib to chemoradiothearpy in high-grade gliomas: a systematic review, meta-analysis, and specific analysis on glioblastoma
Anlotinib, a novel multi-target tyrosine kinase inhibitor, has shown promise in improving survival and managing associated complications. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Anlotinib in patients with high-grade glioma, specifically glioblastoma (GBM). This study was conducted according to the PRISMA guidelines. A systematic search was conducted on PubMed, Embase, Web of Science, and Scopus up to 9 December 2024. The included studies were appraised and assessed for quality and potential bias and further statistical analyses were performed using STATA v.17. A total of 17 studies with 473 patients were recruited, which included 204 patients with GBM. The pooled analysis resulted in a 6-month OS of 67% (95% CI: 42–92%) and a 1-year OS equal to 50% (95% CI: 36–64%) from the Anlotinib treatment. Progression-free survival at 6 months was 61% (95% CI: 46–75%), and at 1 year was 27% (95% CI: 13–41%), also showing similar promising outcomes. The overall response rate (ORR) and disease control rate (DCR) were reported at 55% (95% CI: 44–67%) and 90% (95% CI: 87–94%), respectively. The sub-group analysis revealed that adding anlotinb to temozolomide (TMZ) and radiotherapy had superior outcomes regarding OS, PFS, and DCR. Moreover, the highest ORR and complete response rate were achieved by Anlotinib plus stereotactic radiosurgery. Anlotinib demonstrates considerable efficacy in extending survival and achieving disease control in high-grade glioma patients when added to radiotherapy and TMZ. These findings can support its inclusion in therapeutic regimens, warranting further investigation in large-scale randomized controlled trials.
- Open Access
- 29 December 2025
- Published by Georg Thieme Verlag KG in Asian Journal of Neurosurgery
- Vol. 21 (02) , 284-290
Rigid Cervical Collars after Posterior Cervical Fusion: Do They Improve Outcomes? A Randomized Clinical Trial
To evaluate whether the postoperative use of a rigid cervical collar after posterior cervical decompression and fusion (PCDF) improves neck pain, functional disability, and quality of life in patients with degenerative cervical myelopathy (DCM). A single-blind, randomized controlled trial was conducted involving 60 adult patients with magnetic resonance imaging–confirmed DCM undergoing PCDF at two tertiary centers. Participants were randomly assigned to either a rigid cervical collar group (n = 30) or a no-collar group (n = 30) postoperatively. Outcomes were measured at 1, 3, 6, and 12 months postsurgery. The primary outcome was axial neck pain at 1 month, measured by the visual analog scale (VAS). Secondary outcomes included the neck disability index (NDI) and the 36-Item Short Form Survey (SF-36). Statistical tests included paired t-tests, Mann–Whitney's U tests, and repeated-measures analysis of variance, with all data analysis performed by investigators blinded to group allocation. Post hoc power analysis was conducted to assess statistical sensitivity. Both groups experienced significant improvements in VAS, NDI, and SF-36 scores over time. However, there were no statistically significant differences between the collar and no-collar groups at any measured time point. At 1 month, mean VAS scores were 4.30 ± 0.75 (collar) and 4.07 ± 0.58 (no collar; p = 0.233). Gains in disability and quality-of-life measures surpassed minimal clinically important differences for both groups, but without significant between-group differences. The trial was underpowered (post hoc power = 26.4%) to detect small-to-moderate differences; therefore, outcomes should be interpreted cautiously. The use of a rigid cervical collar after PCDF did not confer additional benefit for neck pain, functional outcomes, or quality of life compared with no collar. These findings suggest that routine rigid cervical collar prescription after PCDF should be reconsidered. Given the study's limited statistical power (26.4%) and lack of surgeon/patient blinding, findings should be interpreted cautiously.
- 29 December 2025
- Published by Georg Thieme Verlag KG in Asian Journal of Neurosurgery
- Vol. 21 (02) , 284-290
Open AccessRigid Cervical Collars after Posterior Cervical Fusion: Do They Improve Outcomes? A Randomized Clinical Trial
To evaluate whether the postoperative use of a rigid cervical collar after posterior cervical decompression and fusion (PCDF) improves neck pain, functional disability, and quality of life in patients with degenerative cervical myelopathy (DCM). A single-blind, randomized controlled trial was conducted involving 60 adult patients with magnetic resonance imaging–confirmed DCM undergoing PCDF at two tertiary centers. Participants were randomly assigned to either a rigid cervical collar group (n = 30) or a no-collar group (n = 30) postoperatively. Outcomes were measured at 1, 3, 6, and 12 months postsurgery. The primary outcome was axial neck pain at 1 month, measured by the visual analog scale (VAS). Secondary outcomes included the neck disability index (NDI) and the 36-Item Short Form Survey (SF-36). Statistical tests included paired t-tests, Mann–Whitney's U tests, and repeated-measures analysis of variance, with all data analysis performed by investigators blinded to group allocation. Post hoc power analysis was conducted to assess statistical sensitivity. Both groups experienced significant improvements in VAS, NDI, and SF-36 scores over time. However, there were no statistically significant differences between the collar and no-collar groups at any measured time point. At 1 month, mean VAS scores were 4.30 ± 0.75 (collar) and 4.07 ± 0.58 (no collar; p = 0.233). Gains in disability and quality-of-life measures surpassed minimal clinically important differences for both groups, but without significant between-group differences. The trial was underpowered (post hoc power = 26.4%) to detect small-to-moderate differences; therefore, outcomes should be interpreted cautiously. The use of a rigid cervical collar after PCDF did not confer additional benefit for neck pain, functional outcomes, or quality of life compared with no collar. These findings suggest that routine rigid cervical collar prescription after PCDF should be reconsidered. Given the study's limited statistical power (26.4%) and lack of surgeon/patient blinding, findings should be interpreted cautiously.
- Open Access
- 20 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41093
Validation of the Persian version of anterior skull base questionnaire in patients undergoing endoscopic transnasal transsphenoidal surgery
Endoscopic skull base surgery has transformed craniofacial treatment by reducing morbidity and enhancing precision. Traditional outcome measures often overlook the multidimensional aspects of quality of life (QoL) in recovery. Patient-reported tools, such as the anterior skull base questionnaire (ASBQ), offer a comprehensive view of QoL. However, the ASBQ's effectiveness is limited in non-English-speaking populations without cultural adaptation. This study aims to culturally adapt and psychometrically validate the Persian version of the anterior skull base questionnaire (ASBQ-P) for patients undergoing transnasal transsphenoidal surgery. Translation and cross-cultural adaptation adhered to ISPOR guidelines, encompassing forward and backward translation, expert review, and cognitive debriefing. Internal consistency was evaluated through Cronbach's α, and test-retest reliability was assessed using intraclass correlation coefficients (ICCs). Convergent validity was assessed using Pearson's correlation with SNOT-22 scores, while responsiveness was evaluated through effect sizes and standardized response means. Statistical analyses were performed using SPSS version 27, with a significance threshold set at P < 0.05. A total of 36 patients completed the Persian version of the ASBQ and SNOT-22 questionnaires. The ASBQ demonstrated excellent internal consistency (Cronbach's α = 0.936). Test-retest reliability was high, with an ICC of 0.927 for average measures. Convergent validity was supported by a significant moderate negative correlation between ASBQ and SNOT-22 scores (r=-0.544, P = 0.001). A known-groups validity analysis revealed significant differences in ASBQ scores across SNOT-22 severity categories (P = 0.001), supporting the instrument's discriminative capacity. Our findings confirm the Persian ASBQ as a reliable and valid tool for assessing outcomes in anterior skull base surgery.
- 20 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41093
Open AccessValidation of the Persian version of anterior skull base questionnaire in patients undergoing endoscopic transnasal transsphenoidal surgery
Endoscopic skull base surgery has transformed craniofacial treatment by reducing morbidity and enhancing precision. Traditional outcome measures often overlook the multidimensional aspects of quality of life (QoL) in recovery. Patient-reported tools, such as the anterior skull base questionnaire (ASBQ), offer a comprehensive view of QoL. However, the ASBQ's effectiveness is limited in non-English-speaking populations without cultural adaptation. This study aims to culturally adapt and psychometrically validate the Persian version of the anterior skull base questionnaire (ASBQ-P) for patients undergoing transnasal transsphenoidal surgery. Translation and cross-cultural adaptation adhered to ISPOR guidelines, encompassing forward and backward translation, expert review, and cognitive debriefing. Internal consistency was evaluated through Cronbach's α, and test-retest reliability was assessed using intraclass correlation coefficients (ICCs). Convergent validity was assessed using Pearson's correlation with SNOT-22 scores, while responsiveness was evaluated through effect sizes and standardized response means. Statistical analyses were performed using SPSS version 27, with a significance threshold set at P < 0.05. A total of 36 patients completed the Persian version of the ASBQ and SNOT-22 questionnaires. The ASBQ demonstrated excellent internal consistency (Cronbach's α = 0.936). Test-retest reliability was high, with an ICC of 0.927 for average measures. Convergent validity was supported by a significant moderate negative correlation between ASBQ and SNOT-22 scores (r=-0.544, P = 0.001). A known-groups validity analysis revealed significant differences in ASBQ scores across SNOT-22 severity categories (P = 0.001), supporting the instrument's discriminative capacity. Our findings confirm the Persian ASBQ as a reliable and valid tool for assessing outcomes in anterior skull base surgery.
- Open Access
- 7 November 2025
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 1-28
Microcargos with Megaeffects: A Literature Review of Immunomodulatory, Diagnostic, Prognostic, and Therapeutic Dimensions of Exosomal MicroRNAs in Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is a complex and aggressive central nervous system (CNS) tumor that has a poor prognosis, and restricted therapeutic options are available despite the increasing research conducted. Moreover, the cells in our body package microRNAs, ubiquitous modulators of numerous biological processes, into exosomes for cell-to-cell signaling. Indeed, exosomal miRNAs contribute to several aspects of glioma, such as development, occurrence, metastasis, and immune evasion. Additionally, exosomal miRNAs play a key role in cellular functions and glioma pathogenesis by regulating numerous pathways, including the Wnt/β-catenin, PTEN/PI3K/Akt, EGFR/MAPK, notch signaling, and NF-κB. Notably, exosomal miRNAs are recognized to have promising potential in clinical applications; in fact, exosomal miRNAs are emerging biomarkers for glioma diagnosis and prognosis and are additionally considered as putative therapeutic candidates by inhibiting tumor progression, occurrence, and metastasis. This review presents the current knowledge regarding clinical potential and application of exosomal miRNAs in glioma, as well as the miRNA-mediated regulatory network underlying glioma immunopathogenesis. Graphical Abstract Different aspects of exosomal microRNA (miRNA) in the diagnosis, prognosis, and therapy of glioblastoma multiforme (GBM). Exosomal miRNAs play a multifaceted role in the diagnosis of GBM, predicting the survival outcome of GBM, and as innovative therapeutic measures for GBM. Additionally, exosomal miRNAs are involved in the immunomodulation of GBM, inducing an immunosuppressive status in microglia, macrophages, and myeloid-derived suppressor cells (MDSCs).
- 7 November 2025
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 1-28
Open AccessMicrocargos with Megaeffects: A Literature Review of Immunomodulatory, Diagnostic, Prognostic, and Therapeutic Dimensions of Exosomal MicroRNAs in Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is a complex and aggressive central nervous system (CNS) tumor that has a poor prognosis, and restricted therapeutic options are available despite the increasing research conducted. Moreover, the cells in our body package microRNAs, ubiquitous modulators of numerous biological processes, into exosomes for cell-to-cell signaling. Indeed, exosomal miRNAs contribute to several aspects of glioma, such as development, occurrence, metastasis, and immune evasion. Additionally, exosomal miRNAs play a key role in cellular functions and glioma pathogenesis by regulating numerous pathways, including the Wnt/β-catenin, PTEN/PI3K/Akt, EGFR/MAPK, notch signaling, and NF-κB. Notably, exosomal miRNAs are recognized to have promising potential in clinical applications; in fact, exosomal miRNAs are emerging biomarkers for glioma diagnosis and prognosis and are additionally considered as putative therapeutic candidates by inhibiting tumor progression, occurrence, and metastasis. This review presents the current knowledge regarding clinical potential and application of exosomal miRNAs in glioma, as well as the miRNA-mediated regulatory network underlying glioma immunopathogenesis. Graphical Abstract Different aspects of exosomal microRNA (miRNA) in the diagnosis, prognosis, and therapy of glioblastoma multiforme (GBM). Exosomal miRNAs play a multifaceted role in the diagnosis of GBM, predicting the survival outcome of GBM, and as innovative therapeutic measures for GBM. Additionally, exosomal miRNAs are involved in the immunomodulation of GBM, inducing an immunosuppressive status in microglia, macrophages, and myeloid-derived suppressor cells (MDSCs).
- 3 November 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-15
The clinical outcomes of combined stereotactic radiosurgery with PD-1/PD-L1 inhibitors in patients with metastatic brain tumors: a systematic review and meta-analysis on the safety and efficacy
Brain metastases (BM) pose a significant challenge due to limited treatment options and poor prognosis. Combining PD-1/PD-L1 inhibitors with stereotactic radiosurgery (SRS) may enhance tumor control through synergistic effects. This study assessed the efficacy and safety of this combined approach for BM. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched PubMed, Embase, Web of Science, and Scopus up to 27 June 2024. Studies involving PD-1/PD-L1 inhibitors and SRS for BM were included. Outcomes included local control (LC), progression-free survival (PFS), overall survival (OS), radiological response, and adverse events. Data were analyzed using STATA V.17 with a random-effects model. Sixteen studies with 1529 patients were included. Pooled 6- and 12-month LC rates were 85% (95% CI 75–95%) and 84% (95% CI 75–93%), respectively. One- and three-year PFS rates were both 51% (95% CI 39–64% and 41–62%), while one- and two-year OS rates were 67% (95% CI 57–78%) and 30% (95% CI 16–45%). Overall response rate was 61% (95% CI 44–78%), with a complete response rate of 39% (95% CI 25–53%). Adverse radiation effects occurred in 31% (95% CI 3–58%), with radiation necrosis in 12% (95% CI 2–23%). Subgroup analyses showed no significant impact of drug type, primary tumor site, prior treatment, or SRS fractionation on outcomes. Combining PD-1/PD-L1 inhibitors with SRS for BM yields robust local control and improved one-year survival compared to historical data, with manageable toxicities. However, variability in outcomes and lack of comparator groups highlight the need for standardized protocols and prospective trials to optimize treatment strategies and identify predictive biomarkers.
- 3 November 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-15
The clinical outcomes of combined stereotactic radiosurgery with PD-1/PD-L1 inhibitors in patients with metastatic brain tumors: a systematic review and meta-analysis on the safety and efficacy
Brain metastases (BM) pose a significant challenge due to limited treatment options and poor prognosis. Combining PD-1/PD-L1 inhibitors with stereotactic radiosurgery (SRS) may enhance tumor control through synergistic effects. This study assessed the efficacy and safety of this combined approach for BM. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched PubMed, Embase, Web of Science, and Scopus up to 27 June 2024. Studies involving PD-1/PD-L1 inhibitors and SRS for BM were included. Outcomes included local control (LC), progression-free survival (PFS), overall survival (OS), radiological response, and adverse events. Data were analyzed using STATA V.17 with a random-effects model. Sixteen studies with 1529 patients were included. Pooled 6- and 12-month LC rates were 85% (95% CI 75–95%) and 84% (95% CI 75–93%), respectively. One- and three-year PFS rates were both 51% (95% CI 39–64% and 41–62%), while one- and two-year OS rates were 67% (95% CI 57–78%) and 30% (95% CI 16–45%). Overall response rate was 61% (95% CI 44–78%), with a complete response rate of 39% (95% CI 25–53%). Adverse radiation effects occurred in 31% (95% CI 3–58%), with radiation necrosis in 12% (95% CI 2–23%). Subgroup analyses showed no significant impact of drug type, primary tumor site, prior treatment, or SRS fractionation on outcomes. Combining PD-1/PD-L1 inhibitors with SRS for BM yields robust local control and improved one-year survival compared to historical data, with manageable toxicities. However, variability in outcomes and lack of comparator groups highlight the need for standardized protocols and prospective trials to optimize treatment strategies and identify predictive biomarkers.
- Open Access
- 1 September 2025
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 16 (5) , 869-878
A Report of Lumbar Disk Herniation Treatment Outcomes: Percutaneous Laser Disk Decompression vs Open Microdiscectomy
Introduction: Lumbar disk herniation (LDH) is one of the most common pathologies leading to radiculopathy. Open microdiscectomy is the gold standard of LDH treatment. However, minimally invasive techniques such as percutaneous laser disk decompression (PLDD) are gaining growing attention. In this study, we retrospectively reviewed the clinical outcomes of patients ...
- 1 September 2025
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 16 (5) , 869-878
Open AccessA Report of Lumbar Disk Herniation Treatment Outcomes: Percutaneous Laser Disk Decompression vs Open Microdiscectomy
Introduction: Lumbar disk herniation (LDH) is one of the most common pathologies leading to radiculopathy. Open microdiscectomy is the gold standard of LDH treatment. However, minimally invasive techniques such as percutaneous laser disk decompression (PLDD) are gaining growing attention. In this study, we retrospectively reviewed the clinical outcomes of patients ...
- Open Access
- 23 May 2025
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 6 (2)
Acute Ischemic Stroke and Endovascular Thrombectomy During COVID-19 Pandemic: A Nationwide Analysis
BACKGROUND AND OBJECTIVES: Infection with COVID-19 may be linked to both higher rates of severe strokes and strokes in younger patients through distinct pathophysiological processes. This study aims to investigate characteristics and outcomes in COVID-19–related acute ischemic stroke (AIS) and endovascular thrombectomy (EVT) included in the National Inpatient Sample database. METHODS: This is a retrospective population-based observational study that includes all patients with COVID-19 and patients with AIS with COVID-19 who underwent EVT and were admitted to hospitals included in the US National Inpatient Sample between 2020 and 2021. Primary outcomes include age difference and difference in cardiovascular risk factors between patients with AIS with and without COVID-19 and EVT patients with and without COVID-19. Secondary outcomes include rates of favorable hospital outcome (defined as discharge to home or acute rehabilitation facility), in-hospital mortality, and the length of hospital stay. RESULTS: A total of 1 381 039 patients with AIS were included. A total of 58 525 had a COVID-19 diagnosis. A total of 83 650 patients underwent EVT, and 3075 of these patients were diagnosed with COVID-19. The mean age for patients with COVID-19 with AIS was lower (67.55 vs 69.40 years; P < .001). There was a higher proportion of Black (21.1% vs 17.9%) and Hispanic patients (15.0% vs 8.5%) among the COVID-19 group of patients with AIS. In adjusted multivariable analyses, the presence of COVID-19 in patients with AIS was significantly associated with a higher rate of inpatient mortality (adjusted odds ratio (AOR): 2.79; 95% CI 2.61-2.98; P < .001) and a lower rate of favorable hospital outcome (AOR: 0.66; 95% CI 0.62-0.70; P < .001). Trend analysis shows that COVID-19–positive AIS cases decreased overall with the rise of the delta variant, but the number of COVID-19–positive AIS cases with the National Institutes of Health Stroke Scale equal to or greater than 10 rose drastically. CONCLUSION: This analysis demonstrates that patients with AIS and concomitant COVID-19 infection were younger, with fewer cardiovascular risk factors, and disproportionately Black and Hispanic, with worse neurological deficit and worse hospital outcome.
- 23 May 2025
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 6 (2)
Open AccessAcute Ischemic Stroke and Endovascular Thrombectomy During COVID-19 Pandemic: A Nationwide Analysis
BACKGROUND AND OBJECTIVES: Infection with COVID-19 may be linked to both higher rates of severe strokes and strokes in younger patients through distinct pathophysiological processes. This study aims to investigate characteristics and outcomes in COVID-19–related acute ischemic stroke (AIS) and endovascular thrombectomy (EVT) included in the National Inpatient Sample database. METHODS: This is a retrospective population-based observational study that includes all patients with COVID-19 and patients with AIS with COVID-19 who underwent EVT and were admitted to hospitals included in the US National Inpatient Sample between 2020 and 2021. Primary outcomes include age difference and difference in cardiovascular risk factors between patients with AIS with and without COVID-19 and EVT patients with and without COVID-19. Secondary outcomes include rates of favorable hospital outcome (defined as discharge to home or acute rehabilitation facility), in-hospital mortality, and the length of hospital stay. RESULTS: A total of 1 381 039 patients with AIS were included. A total of 58 525 had a COVID-19 diagnosis. A total of 83 650 patients underwent EVT, and 3075 of these patients were diagnosed with COVID-19. The mean age for patients with COVID-19 with AIS was lower (67.55 vs 69.40 years; P < .001). There was a higher proportion of Black (21.1% vs 17.9%) and Hispanic patients (15.0% vs 8.5%) among the COVID-19 group of patients with AIS. In adjusted multivariable analyses, the presence of COVID-19 in patients with AIS was significantly associated with a higher rate of inpatient mortality (adjusted odds ratio (AOR): 2.79; 95% CI 2.61-2.98; P < .001) and a lower rate of favorable hospital outcome (AOR: 0.66; 95% CI 0.62-0.70; P < .001). Trend analysis shows that COVID-19–positive AIS cases decreased overall with the rise of the delta variant, but the number of COVID-19–positive AIS cases with the National Institutes of Health Stroke Scale equal to or greater than 10 rose drastically. CONCLUSION: This analysis demonstrates that patients with AIS and concomitant COVID-19 infection were younger, with fewer cardiovascular risk factors, and disproportionately Black and Hispanic, with worse neurological deficit and worse hospital outcome.